SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease

Globally, diabetes mellitus is a leading cause of kidney disease, with a critical percent of patients approaching end-stage kidney disease. In the current era, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as phenomenal agents in halting the progression of kidney disease. Positive...

Full description

Bibliographic Details
Main Authors: Swetha R. Kanduri, Karthik Kovvuru, Panupong Hansrivijit, Charat Thongprayoon, Saraschandra Vallabhajosyula, Aleksandra I. Pivovarova, Api Chewcharat, Vishnu Garla, Juan Medaura, Wisit Cheungpasitporn
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Journal of Clinical Medicine
Subjects:
Diabetes mellitus
SGLT2
SGLT2i
sodium glucose co-transporter 2 inhibitors
nephrology
endocrinology
Online Access:https://www.mdpi.com/2077-0383/9/9/2723

Internet

https://www.mdpi.com/2077-0383/9/9/2723

Similar Items